<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333196</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Key considerations for digital decentralised clinical trials from a feasibility study assessing pacing interventions for long COVID.</ArticleTitle><Pagination><StartPage>22083</StartPage><MedlinePgn>22083</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">22083</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-61827-4</ELocationID><Abstract><AbstractText>Post COVID-19 condition or long COVID is highly prevalent and often debilitating, with key symptoms including fatigue, breathlessness, and brain fog. There is currently a lack of evidence-based treatments for this highly complex syndrome. There is a need for clinical trial platforms to rapidly evaluate nonpharmacological treatments to support affected individuals with symptom management. We co-produced a mixed methods feasibility study to evaluate a multi-arm digital decentralised clinical trial (DCT) platform to assess non-pharmacological interventions for Long COVID, using pacing interventions as an exemplar. The study demonstrated that the platform was able to successfully e-consent participants, randomise them into one of four intervention arms, capture baseline data, and capture outcomes relevant to a health economic evaluation. The study also highlighted several challenges, including difficulties with recruitment, imposter participants, and high attrition rates. We highlight how these challenges can potentially be mitigated to make a fully powered DCT more feasible.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMullan</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Patient Reported Outcome Research, Institute for Applied Health Research, University of Birmingham, Edgbaston, B15 2TT, UK. c.mcmullan@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroon</LastName><ForeName>Shamil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiyegbusi</LastName><ForeName>Olalekan Lee</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Anuradhaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirantharakumar</LastName><ForeName>Krishnarajah</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Elin Haf</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Naijie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alder</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckland</LastName><ForeName>Lewis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyes</LastName><ForeName>Felicity</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Blood and Transplant Research Unit in Precision Transplant and Cellular Therapeutics, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Collaboration West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COV-LT-0013</GrantID><Agency>NIHR</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="Y">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Decentralised trials</Keyword><Keyword MajorTopicYN="N">Feasibility study</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">PROMs</Keyword><Keyword MajorTopicYN="N">Pacing intervention</Keyword></KeywordList><CoiStatement>CM receives funding from the NIHR Surgical Reconstruction and Microbiology Research Centre, the NIHR BTRU in Precision Transplant and Cellular Therapeutics, Innovate UK and Anthony Nolan, and has received personal fees from Aparito outside the submitted work. SH receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI). GMT receives funding from the National Institute for Health and Care Research (NIHR) and UK Research and Innovation (UKRI). SEH receives funding from the NIHR ARC, West Midlands, NIHR BTRU in Precision Transplant and Cellular Therapeutics at the University of Birmingham and Anthony Nolan. SEH declares personal fees from Cochlear and Aparito outside the submitted work. OLA declares personal fees from Gilead Sciences, Merck and GlaxoSmithKline outside the submitted work and receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UKRI), Gilead Sciences, Merck, Anthony Nolan and Sarcoma UK. AS has no declarations during the study period; after the study was completed, she has left the University of Birmingham and taken a post in AstraZeneca. MC received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. In addition, a family member owns shares in GSK. M.C. receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR BTRU in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UKRI), Macmillan Cancer Support, European Regional Development Fund&#x2014;Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK, Anthony Nolan and Gilead Sciences. All other authors declared no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333196</ArticleId><ArticleId IdType="pmc">PMC11436957</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-61827-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-61827-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ONS. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK: 30 March 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023#:~:text=An%20estimated%201.9%20million%20people,as%20of%205%20March%202023%20( (2024).</Citation></Reference><Reference><Citation>WHO. Post COVID-19 Condition (Long COVID). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=It%20is%20defined%20as%20the,months%20with%20no%20other%20explanation (2022).</Citation></Reference><Reference><Citation>Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine38, 101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med.28(8), 1706&#x2013;1714 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi, O. L. et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med.114(9), 428&#x2013;442 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson, S. W. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA328(16), 1604&#x2013;1615 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>JHU. Coronavirus Resources Centre. https://coronavirus.jhu.edu/map.html (2023).</Citation></Reference><Reference><Citation>ONS. Prevalence of Ongoing Symptoms Following Coronavirus (COVID-19) Infection in the UK (ONS, 2022).</Citation></Reference><Reference><Citation>Brown, K. et al. Long COVID and self-management. Lancet399(10322), 355 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776283</ArticleId><ArticleId IdType="pubmed">35065779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford, H. Long-COVID treatments: Why the world is still waiting. Nature608(7922), 258&#x2013;260 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan, J. S. et al. Non-pharmacological therapies for post-viral syndromes, including long COVID: A systematic review. Int. J. Environ. Res. Public Health20, 4 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9967466</ArticleId><ArticleId IdType="pubmed">36834176</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon, S. et al. Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study). BMJ Open12(4), e060413 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="pubmed">35473737</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, G. M. et al. Co-production of a feasibility trial of pacing interventions for Long COVID. Res. Involv. Engage.9(1), 18 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061378</ArticleId><ArticleId IdType="pubmed">36997975</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Norman, G. A. Decentralized clinical trials: The future of medical product development? JACC Basic Transl. Sci.6(4), 384&#x2013;387 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093545</ArticleId><ArticleId IdType="pubmed">33997523</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks, M. A. Core concept: In the wake of COVID-19, decentralized clinical trials move to center stage. Proc. Natl. Acad. Sci. U.S.A.118(47), e2119097118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617428</ArticleId><ArticleId IdType="pubmed">34789570</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodson, N. et al. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit. Med.5(1), 58 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9072305</ArticleId><ArticleId IdType="pubmed">35513479</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi, O. L. et al. Digitally enabled decentralised research: Opportunities to improve the efficiency of clinical trials and observational studies. BMJ Evid. Based Med.28, 328&#x2013;331 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579468</ArticleId><ArticleId IdType="pubmed">36810190</ArticleId></ArticleIdList></Reference><Reference><Citation>Vayena, E., Blasimme, A. &amp; Sugarman, J. Decentralised clinical trials: Ethical opportunities and challenges. Lancet Digit. Health5(6), e390&#x2013;e394 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10129131</ArticleId><ArticleId IdType="pubmed">37105800</ArticleId></ArticleIdList></Reference><Reference><Citation>Torjesen, I. Covid-19: Middle aged women face greater risk of debilitating long term symptoms. BMJ372, n829 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33766927</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakshbandi, G. et al. Home monitoring of lung function, symptoms and quality of life after admission with COVID-19 infection: The HOMECOMIN&#x2019; study. Respirology27(7), 501&#x2013;509 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115460</ArticleId><ArticleId IdType="pubmed">35441433</ArticleId></ArticleIdList></Reference><Reference><Citation>McMullan, C. et al. Usability testing of an electronic patient-reported outcome system linked to an electronic chemotherapy prescribing and patient management system for patients with cancer. Heliyon9(6), e16453 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10227339</ArticleId><ArticleId IdType="pubmed">37260889</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi, O. L. et al. Development and usability testing of an electronic patient-reported outcome measure (ePROM) system for patients with advanced chronic kidney disease. Comput. Biol. Med.101, 120&#x2013;127 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30130638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, A. H. Y. &amp; Honey, M. L. L. User perceptions of mobile digital apps for mental health: Acceptability and usability&#x2014;An integrative review. J. Psychiatr. Ment. Health Nurs.29(1), 147&#x2013;168 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">33604946</ArticleId></ArticleIdList></Reference><Reference><Citation>Catuara-Solarz, S. et al. The efficacy of &#x201c;foundations&#x201d;, a digital mental health app to improve mental well-being during COVID-19: Proof-of-principle randomized controlled trial. JMIR Mhealth Uhealth10(7), e30976 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9255362</ArticleId><ArticleId IdType="pubmed">34978535</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman, V. et al. Feasibility study of a novel digital health platform for patients undergoing transcatheter aortic valve replacement. J. Cardiol. Surg.37(7), 2017&#x2013;2022 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35434823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsetty, A. &amp; Adams, C. Impact of the digital divide in the age of COVID-19. J. Am. Med. Inform. Assoc.27(7), 1147&#x2013;1148 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197532</ArticleId><ArticleId IdType="pubmed">32343813</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehl, J. M. &amp; Harland, D. J. Imposter participants: Overcoming methodological challenges related to balancing participant privacy with data quality when using online recruitment and data collection. Qual. Rep.27(11), 2469&#x2013;2485 (2022).</Citation></Reference><Reference><Citation>Ridge, D. et al. &#x2018;Imposter participants&#x2019; in online qualitative research, a new and increasing threat to data integrity? Health Expect.26(3), 941&#x2013;944 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154888</ArticleId><ArticleId IdType="pubmed">36797816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tishler, C. L. &amp; Bartholomae, S. The recruitment of normal healthy volunteers: A review of the literature on the use of financial incentives. J. Clin. Pharmacol.42(4), 365&#x2013;375 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11936560</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson, B. et al. Designing and using incentives to support recruitment and retention in clinical trials: A scoping review and a checklist for design. Trials20(1), 624 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6842495</ArticleId><ArticleId IdType="pubmed">31706324</ArticleId></ArticleIdList></Reference><Reference><Citation>McMullan, C. et al. Adapting to ulcerative colitis to try to live a &#x2018;normal&#x2019; life: A qualitative study of patients&#x2019; experiences in the Midlands region of England. BMJ Open7(8), e017544 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724065</ArticleId><ArticleId IdType="pubmed">28827271</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, C. et al. How do study design features and participant characteristics influence willingness to participate in clinical trials? Results from a choice experiment. BMC Med. Res. Methodol.22(1), 323 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9756590</ArticleId><ArticleId IdType="pubmed">36526978</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID SOS. https://www.longcovidsos.org/.</Citation></Reference><Reference><Citation>The Therapies for Long COVID in Non-hospitalised Individuals: The TLC Study. https://www.birmingham.ac.uk/research/applied-health/research/tlc-study/index.aspx.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="pubmed">35473737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke, K. et al. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann. Intern. Med.146(5), 317&#x2013;325 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17339617</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman, M. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res.20(10), 1727&#x2013;1736 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestall, J. C., Paul, E. A., Garrod, R., Jones, P. W. &amp; Wedzicha, J. A. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax54(7), 581&#x2013;586 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1745516</ArticleId><ArticleId IdType="pubmed">10377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella, D. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol.34(3 Suppl 2), 13&#x2013;19 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9253779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, S. E. et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ377, e070230 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9043395</ArticleId><ArticleId IdType="pubmed">35477524</ArticleId></ArticleIdList></Reference><Reference><Citation>Spoonie Day. https://www.spoonieday.com/ (2023).</Citation></Reference><Reference><Citation>Medinger, G. The Why, When and How of Pacing|Long Covid&#x2019;s Most Important Lesson. (2021).</Citation></Reference><Reference><Citation>Ensor, H. The Pocket Book of Pacing (Stickman Communications, 2020).</Citation></Reference><Reference><Citation>NHS. Your COVID Recovery. https://www.yourcovidrecovery.nhs.uk/ (2023).</Citation></Reference><Reference><Citation>Staniszewska, S. et al. GRIPP2 reporting checklists: Tools to improve reporting of patient and public involvement in research. BMJ358, j3453 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539518</ArticleId><ArticleId IdType="pubmed">28768629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>